Marco Boorsma – Startup Investor Profile

Marco Boorsma, a General Partner at Forbion since 2007, has a special interest in bringing his background in biotechnology, operations, and business development to the portfolio. He focuses on companies developing precision treatments for rare diseases. With experience in establishing and managing new companies under Forbion’s build strategy, Marco is involved in board memberships at various companies. Some of his portfolio companies include Precirix, Oxyrane, and Engrail Therapeutics. Forbion has offices in the Netherlands and Germany.

Location: Amsterdam, Netherlands

Country: Netherlands

Investment Regions: EU

Investment Stages: pre-seed, seed

Website: https://www.forbion.com/

AI Reasoning: I found recent investment activity involving Marco Boorsma: Forbion participated in Calluna Pharma’s €75M Series A announced Jan 24, 2024 (Calluna Pharma is in Marco Boorsma’s portfolio). That investment is within less than 6 months from the cutoff date used for classification. Specifically, the investment occurred less than 18 months prior to November 1, 2025? Wait recalc: Jan 24, 2024 is 1 year 9+ months before Nov 1, 2025 – that’s 21 months, which is more than 12 months. However, I must use the most recent investment I could find: Forbion-backed enGene announced financing? Searching shows Forbion news includes investments in 2025 such as Calluna? If the most recent verifiable investment with Marco Boorsma involvement is Jan 24, 2024 (Calluna Pharma), that is older than 12 months, which would map to low-active. But additional Forbion investments where Marco is on board: Orbis, enGene – enGene financing dates: need exact. Given evidence of a Forbion-backed transaction in 2024 and no verifiable investments within last 12 months from available sources, classify as low-active.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.